| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Silvano Bosari | Q38544154 |
| Nicola Fusco | Q57152324 | ||
| P2093 | author name string | Silvano Bosari | |
| Nicola Fusco | |||
| P2860 | cites work | Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas | Q35681702 |
| HER2/neu-directed therapy for biliary tract cancer | Q35748129 | ||
| Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer | Q35832274 | ||
| Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis | Q35957036 | ||
| Targeted therapy in gastroesophageal cancers: past, present and future | Q36294579 | ||
| Molecular genetics and targeted therapeutics in biliary tract carcinoma | Q36488070 | ||
| Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis | Q36600002 | ||
| Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | Q36614705 | ||
| Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma | Q36616556 | ||
| Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma | Q36622264 | ||
| HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials | Q36671427 | ||
| Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design | Q37017110 | ||
| Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. | Q37109776 | ||
| HER2 testing in the UK: further update to recommendations | Q37125334 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy | Q37176648 | ||
| EGFR and HER2 expression in advanced biliary tract cancer | Q37362858 | ||
| Combinatorial biomarker expression in breast cancer | Q37682672 | ||
| Clinical and molecular characterization of HER2 amplified-pancreatic cancer. | Q37690146 | ||
| p95HER2 and breast cancer | Q37846003 | ||
| Emerging pathways and future targets for the molecular therapy of pancreatic cancer | Q37912219 | ||
| Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. | Q38030442 | ||
| Medical therapies for hepatocellular carcinoma: a critical view of the evidence | Q38059437 | ||
| Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues | Q38111772 | ||
| Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis | Q38122908 | ||
| Advances in the study of molecularly targeted agents to treat hepatocellular carcinoma. | Q38254939 | ||
| HER2 expression status in diverse cancers: review of results from 37,992 patients | Q38364900 | ||
| Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Q38384113 | ||
| Biliary tract cancers: understudied and poorly understood | Q38445703 | ||
| The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma | Q38447221 | ||
| Heterogeneity of liver cancer and personalized therapy | Q38554914 | ||
| Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis | Q38582925 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Molecular targeted therapy for the treatment of gastric cancer | Q28072433 | ||
| Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates | Q28083123 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| The ErbB/HER family of protein-tyrosine kinases and cancer | Q28302611 | ||
| Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells | Q29616544 | ||
| Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? | Q30856729 | ||
| HER 2/neu protein expression in colorectal cancer | Q33242725 | ||
| A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma | Q33265633 | ||
| Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry | Q33398141 | ||
| Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer | Q33557258 | ||
| Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas | Q33750719 | ||
| Assessment of HER2 status in breast cancer: why, when and how? | Q33877899 | ||
| Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas | Q33943812 | ||
| Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas | Q34029360 | ||
| HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. | Q34324291 | ||
| The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 | ||
| Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas | Q34498746 | ||
| Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer | Q34501536 | ||
| Significance of human epidermal growth factor receptor 2 expression in colorectal cancer | Q34585338 | ||
| Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. | Q34637757 | ||
| Emerging technologies for assessing HER2 amplification | Q34659152 | ||
| Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays | Q35318918 | ||
| Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers | Q35566231 | ||
| Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma | Q35588545 | ||
| Molecular characterization of gallbladder cancer using somatic mutation profiling | Q35597012 | ||
| Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification | Q35633666 | ||
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 | ||
| HER2 overexpression correlates with survival after curative resection of pancreatic cancer. | Q46016285 | ||
| Clinical role of HER-2/neu expression in colorectal cancer. | Q51046708 | ||
| HER-2 amplification is highly homogenous in gastric cancer. | Q51779078 | ||
| Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. | Q52297317 | ||
| Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. | Q52845850 | ||
| HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. | Q52848050 | ||
| Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. | Q52977312 | ||
| Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. | Q53067130 | ||
| Her-2/neu assessment for gastric carcinoma: validation of scoring system. | Q53094440 | ||
| Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. | Q53149260 | ||
| In Situ Hybridization of Breast Cancer Markers. | Q54218865 | ||
| A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. | Q54222781 | ||
| The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies. | Q54333943 | ||
| Comment on Gu et al. entitled "Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis". | Q54365119 | ||
| Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. | Q54594739 | ||
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
| C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study | Q72639491 | ||
| Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma | Q81073375 | ||
| Trastuzumab in the treatment of breast cancer | Q81374982 | ||
| Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections | Q82547098 | ||
| Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future | Q38616838 | ||
| Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer | Q38631363 | ||
| Rediscovering Secondary Tumors of the Prostate in the Molecular Era. | Q38801836 | ||
| Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines | Q39109847 | ||
| The EGF receptor: structure, regulation and potential role in malignancy | Q39152393 | ||
| A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer | Q39772849 | ||
| The epidermal growth factor (EGF). | Q40133809 | ||
| Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma | Q40217601 | ||
| Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine | Q40242682 | ||
| Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). | Q40809042 | ||
| PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas | Q41378259 | ||
| The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions | Q41554100 | ||
| Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab | Q42033747 | ||
| Esophageal cancer chemotherapy: recent advances. | Q43194164 | ||
| Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis | Q43479667 | ||
| c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma | Q43526977 | ||
| HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity | Q43921056 | ||
| Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial | Q44017893 | ||
| C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms | Q44174661 | ||
| HER2 aberrations in cancer: implications for therapy | Q44936056 | ||
| Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu | Q45174616 | ||
| Global cancer statistics | Q22241238 | ||
| Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
| Hepatocellular carcinoma: Where are we? | Q26765182 | ||
| Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer | Q26772969 | ||
| Personalized medicine in gastric cancer: Where are we and where are we going? | Q26774521 | ||
| HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies | Q26822730 | ||
| Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer | Q26864932 | ||
| Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future | Q27013055 | ||
| An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa | Q27027592 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 35 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gastroenterology | Q120569 |
| Erb-b2 receptor tyrosine kinase 2 | Q415271 | ||
| mutation | Q42918 | ||
| gastrointestinal neoplasm | Q58833942 | ||
| tumor biomarker | Q66205818 | ||
| neoplastic gene expression regulation | Q66660300 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 7926-7937 | |
| P577 | publication date | 2016-09-21 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists | |
| P478 | volume | 22 |
| Q64244867 | Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab |
| Q49498310 | Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers. |
| Q64103596 | Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times |
| Q89879114 | HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies |
| Q90626593 | HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population |
| Q37662632 | High levels of serum platelet-derived growth factor-AA and human epidermal growth factor receptor-2 are predictors of colorectal cancer liver metastasis |
| Q50160878 | Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2-positive gastric cancer patients. |
| Q64274212 | Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors |
| Q57037017 | Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma |
| Q33829684 | Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis |
| Q93358900 | Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review |
| Q99712042 | The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells |
| Q55039208 | Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression. |
Search more.